Results 41 to 50 of about 3,371 (214)
Annals of General Psychiatry, 2020 Background Management of schizophrenia is sub-optimal in many patients. Targeting negative symptoms, among the most debilitating aspects of schizophrenia, together with positive symptoms, can result in significant functional benefits and dramatically ...
Andrea Fagiolini +17 more
doaj +1 more source
European Psychiatry, 2022 Introduction The discovery of second-generation antipsychotics represented an authentic breakthrough for the management of psychotic disorders. Nevertheless, they still don’t adequately manage some aspects of these disorders, such as negative symptoms ...
C. Llach +5 more
doaj +1 more source
Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series
Neuropsychiatric Disease and Treatment, 2022 Miguel Bajouco,1– 3 David Mota1,2 1Department of Psychiatry, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 2Institute of Psychological Medicine, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 3Coimbra Institute for ...
Bajouco M, Mota D
doaj
Frontiers in Psychiatry, 2022 Cariprazine is a third-generation antipsychotic medication approved for the treatment of schizophrenia and bipolar disorder, with unique pharmacodynamic and pharmacokinetic properties.
Tommaso Vannucchi +2 more
doaj +1 more source
The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review [PDF]
, 2017 Norepinephrine (NE) is recognized as having a key role in the pathophysiology of major depressive disorder (MDD) and schizophrenia, although its distinct actions via α-adrenergic receptors (α-ARs) are not well defined.
Anna Eramo +4 more
core +1 more source
Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties:A hypothesis based on data [PDF]
, 2023 The treatment of bipolar depression is one of the most challenging needs in contemporary psychiatry. Currently, only quetiapine, olanzapine-fluoxetine combination, lurasidone, cariprazine, and recently lumateperone have been FDA-approved to treat this ...
Fountoulakis, Konstantinos N. +4 more
core +1 more source
Cariprazine in the treatment of psychosis with comorbid cannabis use: A case report
Psychiatry Research Communications, 2022 Past literature highlights that cannabis use increase the risk of developing psychotic disorder. In this case report, the authors describe the employment of cariprazine in the treatment of a young adult male affected by psychosis and co-morbid cannabis ...
Alessandro Gentile +4 more
doaj +1 more source
Cariprazine in Three Special Different Areas: A Real-World Experience
Neuropsychiatric Disease and Treatment, 2021 Camilla Gesi,1 Silvia Paletta,2 Maria Carlotta Palazzo,1 Bernardo Dell’Osso,1,3 Claudio Mencacci,1 Giancarlo Cerveri2 1Department of Mental Health and Addiction, ASST FBF Sacco, Milan, Italy; 2Department of Mental Health and Addiction, ASST Lodi, Lodi ...
Gesi C +5 more
doaj
European Psychiatry, 2022 Introduction Affective symptoms are a common feature of schizophrenia and define bipolar disorder. Alterations in dopamine neurotransmission and activity at D3-D2 receptors is associated with depressive symptoms providing the rationale for targeting D3 ...
R. Mcintyre +3 more
doaj +1 more source
Drug design for CNS diseases: polypharmacological profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies [PDF]
, 2016 Support was kindly provided by the EU COST Action CM1103. DA, KN, and JV kindly acknowledge national project number 172033 and OI1612039 supported by the Ministry of the Republic of Serbia.
Agbaba, Danica +7 more
core +3 more sources